Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer

被引：61

作者：

Saltz, Leonard B. ^{[1
]}

Bach, Peter B. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2014年 / 370卷 / 05期

关键词：

D O I：

10.1056/NEJMc1314761

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: The article by Von Hoff et al. (Oct. 31 issue)(1) is entitled Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. This title strikes us as inappropriately rosy, given the modest benefits and substantial toxic effects observed. The addition of nab-paclitaxel increased the median survival by 1.8 months, or 55 days. The chance of being alive at 2 years was increased from 4% to 9%. Meanwhile, an additional 10% of patients had grade 3 (severe) fatigue. Grade 2 fatigue (moderate, not relieved by rest) and duration of fatigue are not mentioned. Grade 3 (severe) neuropathy was increased ...

引用

页码：478 / 478

页数：1

共 50 条

[21] Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
Carrato, Alfredo
Garcia, Pilar
Lopez, Rafael
Macarulla, Teresa
Rivera, Fernando
Sastre, Javier
Gostkorzewicz, Joana
Benedit, Patricia
Perez-Alcantara, Ferran
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) : 579 - 589
[22] Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer A Phase 1b/2 Pilot Clinical Trial
Jameson, Gayle S.
Borazanci, Erkut
Babiker, Hani M.
Poplin, Elizabeth
Niewiarowska, Anna A.
Gordon, Michael S.
Barrett, Michael T.
Rosenthal, Adam
Stoll-D'Astice, Amy
Crowley, John
Shemanski, Lynn
Korn, Ron L.
Ansaldo, Karen
Lebron, Leticia
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
JAMA ONCOLOGY, 2020, 6 (01) : 125 - 132
[23] Factors affecting peripheral neuropathy induced by nanoparticle albumin-bound paclitaxel in patients with pancreatic cancer
Kang, Minseo
Yoo, Seunghyun
Jung, Yeolmae
Lim, Hayun
Lee, Myeong Hwan
Ryu, Ji Kon
Lee, Jangik I.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (12) : 3232 - 3241
[24] Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer
Pinder, Mary C.
Ibrahim, Nuhad K.
DRUGS OF TODAY, 2006, 42 (09) : 599 - 604
[25] Overview of nanoparticle albumin-bound paclitaxel in metastatic breast cancer
Strauch, Demetria Ileana
Moreno-Aspitia, Alvaro
BREAST CANCER MANAGEMENT, 2013, 2 (03) : 221 - 229
[26] Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
Link, John S.
Waisman, James R.
Nguyen, Bichlien
Jacobs, Cheryl I.
CLINICAL BREAST CANCER, 2007, 7 (10) : 779 - 783
[27] Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer
Link, J. S.
Waisman, J. R.
Nguyen, B.
Jacobs, C. I.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[28] Risk factors for neutropenia during gemcitabine and nanoparticle albumin-bound paclitaxel combination chemotherapy
Yoneyama, Hiroshi
Sasaki, Hisako
Sugawara, Mitsuhiro
Sasaki, Jiichiro
Atsuda, Koichiro
ANNALS OF ONCOLOGY, 2017, 28
[29] Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
Wu, Jing
Wang, Zheng
Li, Jing
Peng, Xue-Hui
Tang, Yi-Chen
Huang, Xiao-Bing
He, Yong-Gang
FRONTIERS IN ONCOLOGY, 2022, 12
[30] Safety and efficacy evaluation of albumin-bound paclitaxel
Cecco, Sara
Aliberti, Maria
Baldo, Paolo
Giacomin, Elisa
Leone, Roberto
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (04) : 511 - 520

← 1 2 3 4 5 →